Gilead Sciences (GILD) Change in Account Payables (2009 - 2026)

Gilead Sciences (GILD) has 18 years of Change in Account Payables data on file, last reported at -$67.0 million in Q1 2026.

• Quarterly Change in Account Payables rose 36.19% year-over-year to -$67.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$94.0 million (down 183.19% YoY) and the FY2025 annual result came in at -$132.0 million, down 145.52% from the prior year.
• Change in Account Payables climbed to -$67.0 million in Q1 2026, from -$95.0 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $359.0 million in Q3 2024 to a low of -$272.0 million in Q1 2023.
• A 5-year average of -$1.8 million and a median of -$43.0 million in 2023 frame the typical range for Change in Account Payables.
• The widest YoY moves for Change in Account Payables: up 1337.93% in 2024, down 2666.67% in 2024.
• Tracing GILD's Change in Account Payables over 5 years: stood at $264.0 million in 2022, then sank by 116.29% to -$43.0 million in 2023, then tumbled by 34.88% to -$58.0 million in 2024, then plunged by 63.79% to -$95.0 million in 2025, then climbed by 29.47% to -$67.0 million in 2026.
• The last three Change in Account Payables figures came in at -$67.0 million (Q1 2026), -$95.0 million (Q4 2025), and $230.0 million (Q3 2025), per Business Quant data.